Clinical Cancer Research · 10 Nov 2026
Prevalence and Actionability of MTAP Loss in Driver Oncogene-Positive and Oncogene-Negative Lung Cancer
Takashi Sakaih-index 9, Zofia Piotrowska, Charlotte I. Wang, Beow Y. Yeap, Mark Sabbagh, Rebecca S. Heist, Jessica J. Lin, Lauren E. Highfield, Jennifer L. Peterson, Mandeep Banwait, Joyce Liang, Manisha Madhavan, Aaron N. Hata, Mari Mino-Kenudson, Ibiayi Dagogo-Jackh-index 15
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Purpose: MTAP loss co-occurs with actionable genomic alterations in NSCLC and creates vulnerability to protein arginine methyltransferase 5 (PRMT5) inhibition. Estimates of prevalence of MTAP loss rely on next-generation sequencing which can underestimate copy losses. Moreover, the activity of PRMT5 inhibitors in oncogene-driven NSCLC is not well established. Experimental Design: We assessed MTAP expression by immunohistochemistry (IHC) in 243 NSCLCs (n=132 early stage, n=111 metastatic), including 33 specimens with paired lymph nodes. Activity of PRMT5 inhibitor monotherapy and in combination with tyrosine kinase inhibitors (TKIs) was evaluated in MTAP-deleted NSCLC cell lines harboring EGFR or KRAS mutations or ALK rearrangements. Results: Among 243 NSCLC specimens from 240 patients (72% with driver alterations, 90% adenocarcinoma), MTAP loss was identified in 42 (17%) specimens, including 17 (13%) early-stage and 22 (20%) metastatic specimens. MTAP loss occurred in 24% of stage 4 driver-positive NSCLCs versus 14% of driver-negative tumors (p=0.314). Twenty-one (64%) lung-nodal pairs demonstrated concordance; eight cases only exhibited decreased MTAP expression in nodes. Variable sensitivity to PRMT5 inhibitors was observed in 22 MTAP-deleted NSCLC cell lines (9 EGFR-mutant, 7 KRAS-mutant, 6 ALK-rearranged), with responses seen in TKI-sensitive and TKI-resistant lines. SDMA (symmetric dimethylarginine) expression did not predict PRMT5 inhibitor sensitivity. TKI + PRMT5 inhibitor combos had greater activity than monotherapy. Conclusions: MTAP loss occurs in 17% of NSCLC, including 24% of oncogene-driven tumors. PRMT5 inhibitor activity is independent of TKI exposure and SDMA expression and enhanced by TKI therapy. These findings support evaluation of PRMT5 inhibitor + TKIs in oncogene-driven NSCLC.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Ibiayi Dagogo-Jack has the highest h-index among the authors (15).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.